Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer

NCT00989690 is registered in ClinicalTrials.gov with Istituto Scientifico H. San Raffaele as lead sponsor.

NCT NCT00989690
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00989690 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Proteomic Stratified Phase III Study of Second-Line Erlotinib Versus Chemotherapy in Patients With Inoperable Non Small Cell Lung Cancer
Lead sponsor
Istituto Scientifico H. San Raffaele
Phase
Phase 3
Overall status
Unknown status
Start date
February 29, 2008
Completion date
Not reported
Enrollment
275 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer